Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Lakshmi Nayak, Nathan Standifer, Jorg Dietrich, Jennifer L Clarke, Gavin P Dunn, Michael Lim, Timothy Cloughesy, Hui K Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y Wen, Mary Macri, Andrew J Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de Los Reyes, Nicholas M Durham, Todd Creasy, Raymond Y Huang, Thomas Kaley, David A Reardon
Clinical cancer research : an official journal of the American Association for Cancer Research 2022;28(12):2567-2578